Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?

Glycemic control is the primary mediator of diabetic microvascular complications and also contributes to macrovascular complications. A new study (see related article beginning on page 1049) reveals a previously unrecognized association between oxidant activation of poly(ADP ribose) polymerase (PARP) and upregulation of known mediators of glycemic injury. Inhibitors of PARP may have potential therapeutic roles in the prevention of diabetic complications.

[1]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[2]  G. Hart,et al.  Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. , 1997, Annual review of biochemistry.

[3]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[4]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[5]  F. GarciaSoriano,et al.  Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase , 2001 .

[6]  Tracey McLaughlin,et al.  Relationship between obesity, insulin resistance, and coronary heart disease risk. , 2002, Journal of the American College of Cardiology.

[7]  L. Geiss,et al.  Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. , 2003, Diabetes care.

[8]  Robert L Hanson,et al.  Components of the "metabolic syndrome" and incidence of type 2 diabetes. , 2002, Diabetes.

[9]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[10]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[11]  I. Goldfine,et al.  Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. , 2000, Diabetes technology & therapeutics.

[12]  M. Laakso,et al.  Glycemic Control and the Risk for Coronary Heart Disease in Patients with Non-Insulin-dependent Diabetes Mellitus: The Finnish Studies , 1996, Annals of Internal Medicine.

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  M. Brownlee.  Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[15]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[16]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[17]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[18]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[19]  É. Szabó,et al.  The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. , 2002, Diabetes.

[20]  L S Geiss,et al.  Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.

[21]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[22]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[23]  P. O'Brien,et al.  The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid , 2003 .

[24]  P. O'Brien,et al.  The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. , 2003, Diabetes care.

[25]  J. Crapo,et al.  Hemodynamic effects of metalloporphyrin catalytic antioxidants: structure-activity relationships and species specificity. , 2002, Free radical biology & medicine.

[26]  G. King,et al.  Molecular understanding of hyperglycemia's adverse effects for diabetic complications. , 2002, JAMA.

[27]  L. Rossetti,et al.  Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. , 2003, The Journal of clinical investigation.

[28]  D. Reed,et al.  Postchallenge Glucose Concentration and Coronary Heart Disease in Men of Japanese Ancestry: Honolulu Heart Program , 1987, Diabetes.

[29]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[30]  L. Wilkins.  Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy , 2001, Neurology.

[31]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[32]  P. Ducimetiere,et al.  New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. , 2001, Journal of the American College of Cardiology.

[33]  M. Laakso,et al.  NIDDM and Its Metabolic Control Predict Coronary Heart Disease in Elderly Subjects , 1994, Diabetes.

[34]  O. Pedersen,et al.  Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. , 2003, Metabolism: clinical and experimental.